Document is current
Any future updates will be listed below
-
Authors
Anan, Intissar https://orcid.org/0000-0003-2874-7643
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04153149 at ClinicalTrials.govnct04136171 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
RNA-based therapies in liver metabolic diseases
https://doi.org/10.1136/gutjnl-2023-331742
nct04136184 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
RNA-based therapies in liver metabolic diseases
https://doi.org/10.1136/gutjnl-2023-331742
Current and emerging treatment options for transthyretin amyloid cardiomyopathy
https://doi.org/10.1136/heartjnl-2024-325184
nct03860935 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
https://doi.org/10.1007/s40120-021-00235-6
RNA-based therapies in liver metabolic diseases
https://doi.org/10.1136/gutjnl-2023-331742
nct05442047 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
https://doi.org/10.1136/jnnp-2021-327909
nct04360434 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
Current and emerging treatment options for transthyretin amyloid cardiomyopathy
https://doi.org/10.1136/heartjnl-2024-325184
Documents that mention this clinical trial
Advances in the treatment of transthyretin amyloidosis
https://doi.org/10.1136/egastro-2025-100198
Current and emerging treatment options for transthyretin amyloid cardiomyopathy
https://doi.org/10.1136/heartjnl-2024-325184
-
Funding
Funding for this research was provided by:
Swedish Research Council (2019-01338)
Swedish Heart-Lung Foundation (20160787)
Region of Västerbotten (RV-987878, RV-978829)
- License Information
